Gesynta Pharma hits halfway mark in groundbreaking endometriosis drug trial

Gesynta Pharma AB has reached a key milestone in its Phase 2 clinical trial for endometriosis treatment. The company has randomised half of the 190 target patients in its NOVA study, testing the drug candidate vipoglanstat. Endometriosis impacts over 10% of women of reproductive age and is a leading cause of infertility. The NOVA trial is a randomised, double-blind, placebo-controlled study assessing vipoglanstat’s efficacy and safety in women with endometriosis across Europe. Vipoglanstat is a novel, non-hormonal, non-opioid drug that targets mPGES-1, an enzyme involved in producing inflammatory mediator PGE2 in endometriotic lesions.

Eva Johnsson, Chief Medical Officer and VP of Clinical Development, stated that reaching the halfway point in patient recruitment is a major achievement for the trial. Previous studies have already confirmed the drug’s safety, tolerability, and positive pharmacodynamic effects in humans. A preclinical study also showed that vipoglanstat significantly reduced pain-related behaviours and the burden of endometriotic lesions.

Patric Stenberg, CEO of Gesynta Pharma, noted that the NOVA trial represents a significant step forward in a field with few ongoing clinical studies. The company remains focused on developing a treatment that is effective, safe, and well-tolerated for endometriosis patients. Top-line results from the NOVA trial are expected in 2027. The trial aims to provide a strong foundation for a potential Phase 3 programme for vipoglanstat. The company continues to prioritise the development of a much-needed therapy for endometriosis.